Skip to main content

FDA Approvals

FDA Approvals
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Read More
FDA Approvals
FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma
Read More
FDA Approvals, Urothelial Cancer, Oncology
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Read More
FDA Approvals
Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma
Read More
FDA Approvals, In the News
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Read More
FDA Approvals, In the News
Mixed Findings in Annual Cancer Statistics Report
Read More
FDA Approvals, In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Read More
FDA Approvals, In the News
Recap of FDA Drug Approvals in 2019
Read More
FDA Approvals, In the News
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Read More
FDA Approvals, In the News
November 11, 2019 — Oncology News & Updates
Read More
Page 12 of 21
Results 111 - 120 of 205